Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis

Cancer Research

Volumn 62, Issue 7, 2002, Pages 2034-2042

  Zhang, Lianglin ^a   Yu, Dihua ^a   Hicklin, Daniel J ^a   Hannay, Jonathan A F ^a   Ellis, Lee M ^a   Pollock, Raphael E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; DOXORUBICIN; FETAL LIVER KINASE 1 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOSE RESPONSE; ENDOTHELIUM CELL; ENZYME ACTIVITY; FEMALE; GROWTH INHIBITION; HISTOPATHOLOGY; IMMUNE DEFICIENCY; LEIOMYOSARCOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTIBODIES, MONOCLONAL; APOPTOSIS; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; DRUG SYNERGISM; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; LEIOMYOSARCOMA; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RHABDOMYOSARCOMA; SOFT TISSUE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0036532055     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Angiogenesis in cancer, vascular, rheumatoid and other diseases
2. Angiogenesis in cancer and other diseases
3. Alitalo receptors and angiogenesis
4. The biology of vascular endothelial growth factor
5. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
6. Failure of blood-island formation and vasculogenesis in Flk-1 deficient mice
7. Role of the Flt-1 receptor tyrosine in regulating the assembly of vascular endothelium
8. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis
9. Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo
10. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumor: Concentration in tumor blood vessel
11. Vascular endothelial growth factor as a marker of tumor endothelium
12. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
13. Oncogenes as inducers of tumor angiogenesis
14. Regulation of angiogenesis via vascular endothelial growth factor receptors
15. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant
16. Target molecules for antiangiogenic therapy: From basic research to clinical trials
17. Anti-angiogenesis, treatment for gliomas: Transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo
18. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo
19. Thomas Inhibition of vascular endothelial growth factor activity by endogenously encoded soluble receptor
20. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types
21. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors
22. Redefining the target: Chemotherapeutic as antiangiogenics
23. Chemotherapeutic drugs-more really is not better
24. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer
25. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity
26. Cancer drugs found to work in new way
27. Recent progress in the classification of soft tissue sarcoma: Role of genetics and clinical implications
28. The epidemiology of soft tissue sarcoma
29. Signal transduction pathways in sarcoma as targets for therapeutic intervention
30. Angiogenesis and antiangiogenic approaches to sarcomas
31. Serum levels of vascular endothelial growth factor and basic fibroblast growth factor in patients with soft-tissue sarcoma
32. Wild-type p53 suppressed angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression
33. 2-terminal fragment of human fibronectin
34. In vitro neutralization of vascular endothelial growth factor activation of Flk-1 by a monoclonal antibody
35. cdc2 kinase
36. Effect of verapamil on the acute toxicity of doxorubicin in vivo
37. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts
38. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel
39. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases
40. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis
41. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: Role of VEGF-receptor 2 and host VEGF-A
42. Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3′-kinase/akt signal transduction pathway